UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. Initial)*
SPACELABS MEDICAL INC.
(Name of Issuer)
COMMON SHARES
(Title of Class of Securities)
846247104
(CUSIP Number)
HAROLD P. HANDS, EXECUTIVE VICE PRESIDENT, LEGAL
MACKENZIE FINANCIAL CORPORATION, 150 BLOOR STREET WEST, SUITE M111,
TORONTO, ONTARIO M5S 3B5 (416) 922-5322
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
April 1, 1997
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b) (3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class).
(See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 846247104 13D Page 2 of 5
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Universal Canadian Growth Fund Limited, by its Investment
Advisor, Mackenzie Financial Corporation
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP * (a) [ ]
(b) [ x ]
3. SEC USE ONLY
4. SOURCE OF FUNDS
Internal, Investment Company Assets
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(E) [ ]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Toronto, Ontario, Canada
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
7. SOLE VOTING POWER
504,500 Shares (through investment advisor, Mackenzie Financial
Corporation)
8. SHARED VOTING POWER
NIL
9. SOLE DISPOSITIVE POWER
504,500 Shares (through investment advisor, Mackenzie Financial
Corporation)
10. SHARED DISPOSITIVE POWER
NIL
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
504,500 Shares
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES. * [ ]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.2%
14. TYPE OF REPORTING PERSON *
IC - Unregistered Investment Company (Canadian Mutual Fund
Corporation)
Schedule 13D Page 3 of 5
Item 1 Security and Issuer
Common Shares
Spacelabs Medical Inc.
15220 N.E. 40th Street
Redmond, WA 98052
Item 2 IDENTITY AND BACKGROUND
Item 2(a) Name
Universal Canadian Growth Fund Limited
Item 2(b) Business Address
150 Bloor Street West, Suite M111
Toronto, Ontario, Canada M5S 3B5
Item 2(c) Principle Business
Canadian Mutual Fund Corporation
Item 2(d) Criminal Convictions
Nil
Item 2(e) Civil Proceedings
Nil
Item 2(f) Citizenship
N/A
Item 3 Source and Amount of Funds or Other Consideration
Purchase price paid from internal source - net assets of
Canadian mutual fund corporation.
Item 4 Purpose of Transaction
The purpose of the transactions reported on this Form Schedule
13D is investment. The reporting entity has acquired the
securities in the ordinary course of business and not with the
purpose nor with the effect of changing or influencing the
control of the issuer, nor in connection with or as participant
in any transaction having such purpose or effect, including any
transaction subject to Rule 13d-3(b) under the Securities and
Exchange Act of 1934, as amended.
Item 5 INTEREST IN SECURITIES OF THE ISSUER
Item 5(a) Aggregate Number and Percentage of Shares Beneficially Owned
504,500 shares, 5.2%
<PAGE>
Schedule 13D Page 4 of 5
Item 5(b) Number of Shares as to which such person has:
(i) Sole power to vote or direct the vote: 504,500 Shares
(through Investment Adviser, Mackenzie Financial Corp.)
(ii) Shared power to vote or direct the vote: NIL
(iii) Sole power to dispose or direct the disposition:504,500 Shares
(through Investment Adviser, Mackenzie Financial Corp.)
(iv) Shared power to dispose or direct the disposition: NIL
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 1, 1997
(iii) Amount: 2,300 Shares
(iv) Price per share: $20.125
(v) Where and how transaction effected: Market Transaction
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 4, 1997
(iii) Amount: 4,800 Shares
(iv) Price per share: $20.375
(v) Where and how transaction effected: Market Transaction
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 14, 1997
(iii) Amount: 6,700 Shares
(iv) Price per share: $20.25
(v) Where and how transaction effected: Market Transaction
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 15, 1997
(iii) Amount: 2,600 Shares
(iv) Price per share: $20.25
(v) Where and how transaction effected: Market Transaction
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 16, 1997
(iii) Amount: 1,200 Shares
(iv) Price per share: $20.1875
Schedule 13D Page 5 of 5
(v) Where and how transaction effected: Market Transaction
Item 5(c) Transactions
(i) Transaction effected by: Universal Canadian
Growth Fund Limited
(ii) Date: April 17, 1997
(iii) Amount: 1,400 Shares
(iv) Price per share: $20.125
(v) Where and how transaction effected: Market Transaction
Item 5(d) Other Interests
Nil
Item 5(e) Date on which reporting person ceased to be beneficial owner of
more than 5%
N/A
Item 6 Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer
N/A
Item 7 Material to be Filed as Exhibits
N/A
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
Harold P. Hands
Executive Vice President, Legal April 30, 1997
